PICC Capital Investment Management
VC Fund
Shanghai, China
PICC Capital Investment Management is a privately owned investment manager.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 54%
Last updated:
For AI agents: llms.txt
Industries PICC Capital Investment Management invests in
Stages PICC Capital Investment Management invests in
Countries PICC Capital Investment Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $1.4M–$2.5B
- Series B
- $16M–$942M
- Series C
- $39M–$1.2B
Investment Focus
Industry
- Biotechnology 10 (38%)
- Health Care 9 (35%)
- Manufacturing 6 (23%)
- Medical 5 (19%)
- Artificial Intelligence 4 (15%)
Stage
- Series A 8 (31%)
- Series B 7 (27%)
- Series C 5 (19%)
- Series D 3 (12%)
- Venture - Series Unknown 3 (12%)
Country
- China 22 (85%)
- United States 2 (8%)
- Japan 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Lingjia Zhang
President
|
President | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Worg Pharmaceuticals
|
Worg Pharmaceuticals is a clinical stage biopharmaceutical company developing new treatments for allergy and other diseases. | $42.6M / Series D / Dec 22, 2025 | |
New Radiomedicine Technology
|
Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $112.2M / Series D / Oct 09, 2025 | |
UNISOC
|
UNISOC is a leading fabless semiconductor company committed to the independent R&D of core chipsets in mobile communications and IoT. Its products cover mobile chipset platforms supporting 2G / 3G / 4G communication standards, RF chipsets, wireless connection chipsets, security chipsets, TV chipsets, and image sensor chipsets. Withmore than 4,500 staff, 14 R&D centers and 7 customer support centers around the world(as of Jan 2018), UNISOC has been the top 3 mobile baseband chipsets supplier in terms of global market share, and the largest pan-chip supplier in China | $552.3M / Venture - Series Unknown / Jun 03, 2024 | |
Shanghai Desano Pharmaceuticals Investment
|
Desino was founded in 1996 and is headquartered in Shanghai Zhangjiang Hi-Tech Park. The company's anti-AIDS drugs and anti-malarial drugs are the core development areas for the global public health crisis, and are committed to the development, production, registration and global sales of high-quality drugs.The Dyson Company R&D Center islocated in Shanghai and is the National Enterprise Technology Center, the National Anti-AIDS Drug Engineering Technology Research Center and the National Postdoctoral Research Station. | Venture - Series Unknown / Feb 02, 2023 | |
Asia Pacific Medical Group
|
APMG is an early foreign-funded medical institution that entered the field of medical services in China. | Series A / Nov 16, 2022 | |
Atech Automotive Electronics
|
Atech Automotive Electronics is a company that designs, develops, manufactures and sells various automotive electronic products | $69M / Series C / Nov 08, 2022 | |
GAC Aion New Energy Automobile
|
GAC Aion New Energy Automobile is a Chinese electric vehicle marque of Guangzhou Automobile Corporation. The company was introduced in 2018 as a sub-brand and in 2020 as a marque. | $2.5B / Series A / Oct 21, 2022 | |
|
Doma Biopharmaceutical
|
Doma Biopharmaceutical is a biotech company. | $142.1M / Series A / Jun 01, 2022 | |
Ingeek
|
Ingeek provides information security consulting and services. | Series B / Apr 11, 2022 | |
METiS Pharmaceuticals
|
METiS Pharmaceuticals is the world's first AI-driven drug formulation company. | $150M / Series B / Apr 06, 2022 | |
| See all 26 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does PICC Capital Investment Management invest in?
PICC Capital Investment Management invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Series A and Series B stage. Most of the 26 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is PICC Capital Investment Management's check size?
PICC Capital Investment Management typically joins rounds of $1.4M–$2.5B at Series A, $16M–$942M at Series B and $39M–$1.2B at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds PICC Capital Investment Management participates in.
How do I contact PICC Capital Investment Management?
Public channels for PICC Capital Investment Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at PICC Capital Investment Management?
The team at PICC Capital Investment Management includes Lingjia Zhang (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
